Selexipag, a groundbreaking medication for pulmonary arterial hypertension (PAH), represents a significant achievement in medicinal chemistry. As a selective and orally active prostacyclin receptor (IP receptor) agonist, it offers a therapeutic advantage over traditional treatments. The development of such sophisticated pharmaceuticals hinges on the availability and precise synthesis of their chemical building blocks. At the heart of Selexipag's molecular framework lies the intermediate, 4-(Isopropylamino)butanol (CAS: 42042-71-7). This molecule provides a crucial structural element that is elaborated through a series of chemical transformations to yield the final active pharmaceutical ingredient. The synthesis route often involves reacting Selexipag precursors with this specific butanol derivative. The efficiency and outcome of these reactions are highly dependent on the quality and purity of the 4-(Isopropylamino)butanol used. NINGBO INNO PHARMCHEM CO.,LTD. specializes in producing this intermediate with high purity, ensuring that pharmaceutical developers can rely on its consistent performance in their complex synthetic pathways. Understanding the chemical properties and synthesis of 4-(Isopropylamino)butanol is key to appreciating the intricate process of drug development and the importance of a stable supply chain for essential chemical intermediates.